382 related articles for article (PubMed ID: 27046479)
1. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
Alba M; Xie J; Fung A; Desai M
Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
[TBL] [Abstract][Full Text] [Related]
2. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
3. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
Jackson K; Moseley KF
Curr Osteoporos Rep; 2020 Oct; 18(5):439-448. PubMed ID: 32710428
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
Bilezikian JP; Watts NB; Usiskin K; Polidori D; Fung A; Sullivan D; Rosenthal N
J Clin Endocrinol Metab; 2016 Jan; 101(1):44-51. PubMed ID: 26580234
[TBL] [Abstract][Full Text] [Related]
5. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Qiu R; Balis D; Xie J; Davies MJ; Desai M; Meininger G
Curr Med Res Opin; 2017 Mar; 33(3):553-562. PubMed ID: 27977934
[TBL] [Abstract][Full Text] [Related]
6. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
[TBL] [Abstract][Full Text] [Related]
7. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Weir MR; Kline I; Xie J; Edwards R; Usiskin K
Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
[TBL] [Abstract][Full Text] [Related]
9. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
[TBL] [Abstract][Full Text] [Related]
10. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
Trials; 2020 May; 21(1):379. PubMed ID: 32370806
[TBL] [Abstract][Full Text] [Related]
11. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
Li X; Li T; Cheng Y; Lu Y; Xue M; Xu L; Liu X; Yu X; Sun B; Chen L
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3170. PubMed ID: 30983141
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of canagliflozin in type 2 diabetes mellitus.
Perkovic V; Jardine M; Vijapurkar U; Meininger G
Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
[TBL] [Abstract][Full Text] [Related]
13. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
Fralick M; Kim SC; Schneeweiss S; Kim D; Redelmeier DA; Patorno E
Ann Intern Med; 2019 Feb; 170(3):155-163. PubMed ID: 30597484
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
Nigro SC; Riche DM; Pheng M; Baker WL
Ann Pharmacother; 2013 Oct; 47(10):1301-11. PubMed ID: 24259694
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
16. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
18. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Messana JA; Schwartz SS; Townsend RR
Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms.
Filippatos TD; Tsimihodimos V; Liamis G; Elisaf MS
Diabetes Metab Syndr; 2018; 12(1):59-63. PubMed ID: 28826578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
